Pharsight

Tecfidera is owned by Biogen Inc.

Tecfidera contains Dimethyl Fumarate.

Tecfidera has a total of 9 drug patents out of which 0 drug patents have expired.

Tecfidera was authorised for market use on 27 March, 2013.

Tecfidera is available in capsule, delayed release;oral dosage forms.

Tecfidera can be used as method of treating multiple sclerosis, method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine.

The generics of Tecfidera are possible to be released after 16 November, 2035.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399514	BIOGEN INC	Treatment for multiple sclerosis	Feb, 2028 (5 years from now)
US10994003	BIOGEN INC	Dimethyl fumarate and vaccination regimens	Mar, 2035 (12 years from now)
US10555993	BIOGEN INC	Dimethyl fumarate and vaccination regimens	Mar, 2035 (12 years from now)
US10391160	BIOGEN INC	Dimethyl fumarate and vaccination regimens	Mar, 2035 (12 years from now)
US11007167	BIOGEN INC	Methods of treating multiple sclerosis	Nov, 2035 (12 years from now)
US11246850	BIOGEN INC	Methods of treating multiple sclerosis	Nov, 2035 (12 years from now)
US10959972	BIOGEN INC	Methods of treating multiple sclerosis	Nov, 2035 (12 years from now)
US11129806	BIOGEN INC	Methods of treating multiple sclerosis	Nov, 2035 (12 years from now)
US11007166	BIOGEN INC	Methods of treating multiple sclerosis	Nov, 2035 (12 years from now)

Exclusivity	Exclusivity Expiration
M	Feb 5, 2023

Drugs and Companies using DIMETHYL FUMARATE ingredient

Market Authorisation Date: 27 March, 2013

Treatment: Method of treating multiple sclerosis; Method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine

Dosage: CAPSULE, DELAYED RELEASE;ORAL